Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

AbbVie Selloff Is A Buying Opportunity

By Geoff Considine, Ph.DStock MarketsSep 13, 2021 08:25AM ET
www.investing.com/analysis/abbvie-selloff-is-a-buying-opportunity-200601710
AbbVie Selloff Is A Buying Opportunity
By Geoff Considine, Ph.D   |  Sep 13, 2021 08:25AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

AbbVie (NYSE:ABBV) has recently suffered a sell-off, triggered by the Aug. 31 FDA announcement that the packaging of Rinvoq, its prescription drug for rheumatoid arthritis, will require a warning about very serious side effects. ABBV is relying on Rinvoq to offset the anticipated decline in sales of Humira, ABBV’s current blockbuster drug, that comes off patent in 2023.

ABBV shares have fallen 11.5%, from a close of $120.75 on Aug. 31 to the current level, $106.87. Analysts don’t expect the new label to have a major impact and see the share price decline as an over-reaction. An additional concern for ABBV and other pharma stocks is that the White House has recently endorsed allowing the federal government to negotiate drug costs.

ABBV Daily
ABBV Daily

Over longer time horizons, ABBV’s total returns are a mixed bag. With the recent declines, ABBV has a YTD total return of only 3.75%, far below the Drug Manufacturer industry. ABBV has also lagged the industry over the past 3 years, the stock has solidly beaten the industry return over the trailing 5-year period. ABBV was spun off from Abbott Labs (NYSE:ABT) in 2013, so there is not yet 10 years of performance data.

ABBV Trailing Total Return Vs. Drug Manufacturer Industry And Total US Equity Market
ABBV Trailing Total Return Vs. Drug Manufacturer Industry And Total US Equity Market

Source: Morningstar.com

One of the notable features of ABBV is its modest valuation. The forward dividend yield is 4.85% and the forward P/E is 7.74. At these levels, the earnings don’t require much growth to make the shares look attractive. The 3- and 5-year dividend growth rates are 15.8% and 18.0% annualized, respectively.

The combination of the current yield and the dividend growth rate makes an attractive value proposition. ABBV has beaten EPS expectations for 10 consecutive quarters and the last miss, on Jan. 25, 2019, was only $0.04 on quarterly EPS of $1.90 (consensus expectation was $1.94). The company is doing a good job of steadily growing earnings and setting expectations.

To form an opinion of ABBV, I rely on two forms of consensus outlooks. The first is the well-known Wall Street analyst consensus. When there is not too much dispersion among the analyst price targets, the consensus has predictive value. The second form of consensus outlook that I track is the market-implied outlook, derived from the market prices of options.

The price of an option represents the market’s consensus estimate for the probability that the price will rise above (call option) or fall below (put option) a specific level (the strike price) from today until the option expiration date. Analyzing the market prices of calls and puts at a range of strikes, but a common expiration date, it is possible to calculate the probabilities of all possible price returns that best reconcile the options prices for the period.

For those who are unfamiliar with this concept, I have written an overview, including links to the relevant financial literature. More generally, it is worth having a look at the research on the value of consensus estimates, which are often more accurate than even the best individual estimates that are part of the consensus.

I last analyzed ABBV on May 2, 2021 and I gave the stock a bullish rating to early 2022. Since then, the total return on ABBV is -4.03%.

ABBV Performance
ABBV Performance

Source: Seeking Alpha

Idiosyncratic surprises are not uncommon with individual stocks and occur with greater frequency among pharma stocks. Failure or success on a clinical trial, for example, typically shocks the share price. The recent FDA announcement has triggered a substantial short-term decline. I am updating my analysis to see whether the longer-term outlook for ABBV has changed.

Wall Street Analyst Consensus Outlook for ABBV

eTrade’s calculation of Wall Street consensus combines the views of 13 ranked analysts who have published ratings and price targets within the past 90 days. The consensus rating is bullish and the consensus 12-month price target is 20.6% above the current price. Even the lowest price target is 5% above the current price. The consensus price target was $127.50 when I analyzed ABBV in May.

Wall Street Consensus Rating And 12-month Price Target
Wall Street Consensus Rating And 12-month Price Target

Source: eTrade

Investing.com’s calculation of Wall Street consensus is derived from the views of 24 analysts who have published ratings and price targets over the past 90 days. The consensus rating is bullish (outperform) and the consensus 12-month price target is $125.19, implying a 17.4% price appreciation.

Wall Street Consensus Rating And 12-month Price Target
Wall Street Consensus Rating And 12-month Price Target

Source: Investing.com

Today, as in May, the prevailing outlook for ABBV from the analysts is bullish. Combining the dividend and the consensus price outlook, the expected 12-month total return is 23.8% (taking the average of the two consensus price targets). A key question, even taking the analyst consensus at face value, is whether the risk associated with ABBV makes this an attractive risk-return proposition.

Market-Implied Outlook for ABBV

I have analyzed call and put options at a range of strikes for two expiration dates, Jan. 21, 2022 and June 17, 2022, to generate market-implied outlooks for the next 4.3 months and the next 9.1 months. When I calculate the theoretical prices of the options using the market-implied outlook, the theoretical prices match the market prices to within an average of 0.4% of the market prices of the options.

The standard presentation of the market-implied outlook is a probability distribution of return, with probability on the vertical axis and price return on the horizontal.

Market-Implied Price Return Probabilities From Now Until Jan. 21, 2022
Market-Implied Price Return Probabilities From Now Until Jan. 21, 2022

Source: Author’s calculations using options quotes from eTrade

The market-implied outlook for the next 4.3-months is very symmetric, with similar probabilities of positive and negative returns of the same magnitude. There is a very slight positive tilt, with the peak probability corresponding to a price return of +1%, but this is not large enough to be considered meaningful. The annualized volatility derived from this distribution is 27%.

To make it easier to directly compare the probabilities of positive and negative returns, I look at a version of the market-implied outlook with the negative return side of the distribution rotated about the vertical axis (see chart below).

Market-Implied Price Return Probabilities From Now Until Jan. 21, 2022
Market-Implied Price Return Probabilities From Now Until Jan. 21, 2022

Source: Author’s calculations using options quotes from eTrade. The negative return side of the distribution has been rotated about the vertical axis.

The probabilities of positive and negative returns of the same magnitude are very similar (the red dashed line and the solid blue line are very close). If anything, there are very slightly higher probabilities of negative returns.

We expect the market-implied outlook to have a negative bias for dividend-paying stocks because the dividends reduce the upside potential relative to the downside. In addition, theory suggests that there should be a negative bias because investors tend to be risk averse, and therefore willing to pay more than fair value for put options. In light of these two considerations, and especially because ABBV pays such a large dividend, this market-implied outlook to Jan. 21, 2022 is modestly bullish.

In my analysis in May, the market-implied outlook to Jan. 21, 2022 was notably negatively tilted and, considering the large dividend and the tendency for a negative bias in these outlooks, I interpreted the results as neutral with a slight negative (bearish) tilt. The current market-implied outlook to Jan. 21, 2022 is substantially more bullish than back in May.

Market-Implied Price Return Probabilities From Now Until June 17, 2022
Market-Implied Price Return Probabilities From Now Until June 17, 2022

Source: author’s calculations using options quotes from eTrade. The negative return side of the distribution has been rotated about the vertical axis.

The market-implied outlook for the next 9.1 months (calculated using options expiring on June 17, 2022) shows an elevated probability of negative returns (red dashed line meaningfully above the solid blue line). I interpret this as neutral with a slight bearish tilt. The annualized volatility derived from this distribution is 27%.

Summary

The recent selloff in ABBV presents a buying opportunity. The Wall Street consensus is that the impact of the new FDA labeling requirement for Rinvoq is not going to be substantial.

The consensus 12-month price targets imply almost 20% in price appreciation, for expected total return of 23.8%. The market-implied outlook to January 2022 has improved substantially since my last analysis in May, going from neutral with a bearish tilt to modestly bullish. The expected volatility is 27% (annualized).

As a rule of thumb, I want to see an expected 12-month return of at least half the value of the expected volatility. If the expected return is anywhere close to the analyst consensus of 23.8%, ABBV easily surpasses this threshold.

Given the slightly bullish market-implied outlook to early 2022 and the Wall Street outlook, I am bullish overall for ABBV. The bearish tilt in the market-implied outlook to June 2022 suggests revisiting this analysis in early 2022.

AbbVie Selloff Is A Buying Opportunity
 

Related Articles

AbbVie Selloff Is A Buying Opportunity

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (4)
ayomidele oyedokun
ayomidele oyedokun Sep 14, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ayomidele oyedokun
ayomidele oyedokun Sep 14, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i don't know to
Ajay Uppal
Ajay Uppal Sep 13, 2021 1:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
all sell off are buying opportunity for the sellers but don't know why they are selling.. and don't understand
Alberto Martini
Alberto Martini Sep 13, 2021 12:06PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
bmy same territory?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email